The discovery of potent, orally bioavailable pyrazolo and triazolopyrimidine CXCR2 receptor antagonists

被引：21

作者：

Porter, David W. ^{[1
]}

Bradley, Michelle ^{[1
]}

Brown, Zarin ^{[1
]}

Canova, Riccardo ^{[2
]}

Charlton, Steven ^{[1
]}

Cox, Brian ^{[1
]}

Hunt, Peter ^{[1
]}

Kolarik, David ^{[2
]}

Lewis, Sarah ^{[1
]}

O'Connor, Des ^{[1
]}

Reilly, John ^{[1
]}

Spanka, Carsten ^{[2
]}

Tedaldi, Lauren ^{[1
]}

Watson, Simon J. ^{[1
]}

Wermuth, Roland ^{[2
]}

Press, Neil J. ^{[1
]}

机构：

[1] Novartis Inst BioMed Res, Horsham Res Ctr, Horsham RH12 5AB, W Sussex, England

[2] Novartis Inst BioMed Res, CH-4056 Basel, Switzerland

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2014年 / 24卷 / 01期

关键词：

CXCR2; Chemokines; Pyrazolopyrimidine; Triazolopyrimidine; Neutrophils; COPD; HIT-TO-LEAD; PULMONARY-DISEASE; INTERLEUKIN-8;

D O I：

10.1016/j.bmcl.2013.11.074

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A hit-to-lead optimisation programme was carried out on the Novartis archive screening hit, pyrazolopyrimidine 2-methyl-5-((phenylthio)methyl)pyrazolo[1,5-a]pyrimidin-7-ol 1, resulting in the discovery of CXCR2 receptor antagonist 2-benzyl-5-(((2,3-difluorophenyl)thio)methyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-ol 14. The SAR was investigated by systematic variation of the pendant thiol, alkyl and pyrimidinol groups. Replacement of the pyrazolopyrimidine core with a triazolo alternative led to a dual series of antagonists with favourable biological and pharmacokinetic properties. (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：72 / 76

页数：5

共 50 条

[1] Discovery of potent and orally bioavailable N,N′-diarylurea antagonists for the CXCR2 chemokine receptor
Jin, Q
Nie, H
McCleland, BW
Widdowson, KL
Palovich, MR
Elliott, JD
Goodman, RM
Burman, M
Sarau, HM
Ward, KW
Nord, M
Orr, BM
Gorycki, PD
Busch-Petersen, J
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (17) : 4375 - 4378
[2] Hit-to-lead studies: The discovery of potent, orally bioavailable triazolethiol CXCR2 receptor antagonists
Baxter, A
Bennion, C
Bent, J
Boden, K
Brough, S
Cooper, A
Kinchin, E
Kindon, N
McInally, T
Mortimore, M
Roberts, B
Unitt, J
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (16) : 2625 - 2628
[3] Hit-to-lead studies: The discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists
Baxter, A
Cooper, A
Kinchin, E
Moakes, K
Unitt, J
Wallace, A
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (04) : 960 - 963
[4] The discovery of potent, orally bioavailable pyrimidine-5-carbonitrile-6-alkyl CXCR2 receptor, antagonists
Porter, David W.
Bradley, Michelle
Brown, Zarin
Charlton, Steven J.
Cox, Brian
Hunt, Peter
Janus, Diana
Lewis, Sarah
Oakley, Paul
O'Connor, Des
Reilly, John
Smith, Nichola
Press, Neil J.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (15) : 3285 - 3290
[5] Diaminocyclobutenediones as potent and orally bioavailable CXCR2 receptor antagonists: SAR in the phenolic amide region
Aki, Cynthia
Chao, Jianping
Ferreira, Johan A.
Dwyer, Michael P.
Yu, Younong
Chao, Jianhua
Merritt, Robert J.
Lai, Gaifa
Wu, Minglang
Hipkin, R. William
Fan, Xuedong
Gonsiorek, Waldemar
Fosseta, James
Rindgen, Diane
Fine, Jay
Lundell, Daniel
Taveras, Arthur G.
Biju, Purakkattle
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (15) : 4446 - 4449
[6] C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists
Chao, Jianhua
Taveras, Arthur G.
Chao, Jianping
Aki, Cynthia
Dwyer, Michael
Yu, Younong
Purakkattle, Biju
Rindgen, Diane
Jakway, James
Hipkin, William
Fosetta, James
Fan, Xuedong
Lundell, Daniel
Fine, Jay
Minnicozzi, Michael
Phillips, Jonathan
Merritt, J. Robert
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (13) : 3778 - 3783
[7] New class of orally bioavailable CXCR2 antagonists.
Jin, Q
Nie, H
McCleland, BW
Elliott, JD
Lee, JM
Schmidt, DM
Sarau, HM
White, JR
Dede, KA
Jurewicz, AJ
Luzietti, RA
Foley, JJ
Gorycki, P
Salyers, KL
Widdowson, K
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 221 : U46 - U46
[8] Discovery of potent, orally bioavailable protease-activated receptor 4 antagonists
Marinier, Anne
Banville, Jacques
Bird, Eileen
Callejo, Mario
Deon, Daniel
Dube, Laurence
Gagnon, Marc
Giancarli, Mary
Guy, Julia
Harper, Tim
Lam, Patrick
Lavallee, Jean-Francois
Lawrence, Michael
Martel, Alain
Miller, Michael
O'Grady, Harold
Posy, Shoshana
Priestley, Scott
Remillard, Roger
Ruediger, Edward
Tremblay, Francois
Watson, Carol
Wong, Pancras
Yang, Jing
Bouvier, Michel
Seiffert, Dietmar
Wexler, Ruth
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
[9] Discovery of novel, potent and orally bioavailable CRTH2 antagonists
Terasaka, Tadashi
Ito, Shinji
Zenkoh, Tatsuya
Hayashida, Hisashi
Matsuda, Hiroshi
Miyata, Junji
Nagata, Hiroshi
Takasuna, Yuji
Kobayashi, Miki
Takeuchi, Makoto
Ohta, Mitsuaki
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 241
[10] Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists
Lu, Hongfu
Yang, Ting
Xu, Zhongmiao
Lin, Xichen
Ding, Qian
Zhang, Yueting
Cai, Xin
Dong, Kelly
Gong, Sophie
Zhang, Wei
Patel, Metul
Copley, Royston C. B.
Xiang, Jianing
Guan, Xiaoming
Wren, Paul
Ren, Feng
JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (06) : 2518 - 2532

← 1 2 3 4 5 →